Skip to Content
Merck
CN
  • Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression.

Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression.

PloS one (2014-05-08)
Linda Ravenna, Lorenzo Principessa, Alessandra Verdina, Luisa Salvatori, Matteo Antonio Russo, Elisa Petrangeli
ABSTRACT

Hypoxia and inflammation are strictly interconnected both concurring to prostate cancer progression. Numerous reports highlight the role of tumor cells in the synthesis of pro-inflammatory molecules and show that hypoxia can modulate a number of these genes contributing substantially to the increase of cancer aggressiveness. However, little is known about the importance of the tumor phenotype in this process. The present study explores how different features, including differentiation and aggressiveness, of prostate tumor cell lines impact on the hypoxic remodeling of pro-inflammatory gene expression and malignancy. We performed our studies on three cell lines with increasing metastatic potential: the well differentiated androgen-dependent LNCaP and the less differentiated and androgen-independent DU145 and PC3. We analyzed the effect that hypoxic treatment has on modulating pro-inflammatory gene expression and evaluated the role HIF isoforms and NF-kB play in sustaining this process. DU145 and PC3 cells evidenced a higher normoxic expression and a more complete hypoxic induction of pro-inflammatory molecules compared to the well differentiated LNCaP cell line. The role of HIF1α and NF-kB, the master regulators of hypoxia and inflammation respectively, in sustaining the hypoxic pro-inflammatory phenotype was different according to cell type. NF-kB was observed to play a main role in DU145 and PC3 cells in which treatment with the NF-kB inhibitor parthenolide was able to counteract both the hypoxic pro-inflammatory shift and HIF1α activation but not in LNCaP cells. Our data highlight that tumor prostate cell phenotype contributes at a different degree and with different mechanisms to the hypoxic pro-inflammatory gene expression related to tumor progression.

MATERIALS
Product Number
Brand
Product Description

Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Parthenolide, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human NT5E
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
USP
Glycerin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human NTS
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Glycerol, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glycerol, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Glycerol, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glycerol, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Sigma-Aldrich
Glycerol, Vetec, reagent grade, 99%
Sigma-Aldrich
Glycerol, puriss., anhydrous, 99.0-101.0% (alkalimetric)
Sigma-Aldrich
Glycerol, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)
Supelco
Glycerol, analytical standard
Sigma-Aldrich
Glycerol, ≥99.5%
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerin, meets USP testing specifications